« Previous
Next »
American Journal of Ophthalmology
Volume 138, Issue 4
, Pages 547-553
, October 2004
Corneal pharmacokinetics of topically applied azithromycin and clarithromycin
References
- Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis . Am J Ophthalmol . 2001;132:819–830
- . Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal . Am J Ophthalmol . 2000;129:382–384
- Nontuberculous mycobacterial keratitis in South Florida . Ophthalmology . 1998;105:1652–1658
- An outbreak of Mycobacterium chelonae infection after LASIK . Ophthalmology . 2003;110:276–285
- . Delayed-onset mycobacterial keratitis after LASIK . Cornea . 2002;21:546–554
- Mycobacterium keratitis after laser in situ keratomileusis . J Refract Surg . 2000;16:191–195
- Infectious keratitis after LASIK . Ophthalmology . 2003;110:503–510
- . Infectious keratitis after laser refractive surgery . Ophthalmology . 2001;108:1266–1268
- Mycobacterium interface keratitis after laser in situ keratomileusis . Ophthalmology . 2001;108:2201–2208
- . Mycobacterium chelonae interface infection after endokeratoplasty . Am J Ophthalmol . 2003;135:393–395
- . Corneal pharmacokinetics of topical clarithromycin . Invest Ophthalmol Vis Sci . 1995;36:965–968
- Comparison of topical antibiotics for treating Mycobacterium fortuitum keratitis in an animal model . Am J Ophthalmol . 1993;116:700–707
-
.
Methods for the study of irritation and toxicity of substances applied to the skin and mucous membranes
.
J Pharmacol Exp Toxicol
. 1944;82:377–390
- Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes . J Vet Pharmacol Ther . 2002;25:99–9104
- . Azithromycin potency determination: optimal conditions for microbiological diffusion method assay . J Pharm Biomed Anal . 1998;17:903–910
-
Lauderdale T, Chapin KC, Murray, PR. Reagents. In: Murray PR, Baron EJ, Pfaller MA, et al, editors. Manual of clinical microbiology, 7th ed. Washington, DC: ASM Press, 1999: 1669.
-
Steigbigel NH. Macrolides and clarithromycin. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, editors, 5th ed. Philadelphia: Churchill Livingstone, 2000:371–374.
- . Erythromycin, clarithromycin, and azithromycin: are the differences real? . Clin Ther . 1996;18:56–72
-
Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992;36:180–184.
- . Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin . Clin Ther . 1997;19:626–638
- . Comparative activity of azithromycin against clinical isolates of mycobacteria . J Antimicrob Chemother . 1996;38:539–542
Supported in part by Research to Prevent Blindness, Inc., New York, NY (G.N.H., B.J.M.), the Jules Stein Eye Institute Card Family Research Fund and Wasserman Fund (B.J.M.), the Skirball Foundation, Los Angeles, CA (G.N.H.), and the David May II Endowed Professorship (G.N.H.). Dr. Holland is a recipient of a Research to Prevent Blindness, Physician-Scientist Award.
PII: S0002-9394(04)00509-4
doi: 10.1016/j.ajo.2004.04.071
© 2004 Elsevier Inc. All rights reserved.
« Previous
Next »
American Journal of Ophthalmology
Volume 138, Issue 4
, Pages 547-553
, October 2004
